IMMUNOGEN COMPLETES PUBLIC OFFERINGImmunoGen Inc. of Cambridge, Mass., on Wednesday completeda previously announced public offering of 2 million shares ofcommon stock at $19 per share, raising $38 million lessunderwriting fees. There is an overallotment of 300,000 shares.The company (NASDAQ:IMGN) develops immunoconjugates totreat cancer.


Epitope Inc. of Beaverton, Ore., on Thursday said the Food andDrug Administration has licensed its EPIblot HIV-1 WesternBlot confirmatory test. Prior to obtaining the license, the testwas limited to research applications. The test is used to confirmthe result when an AIDS screening test returns a positiveoutcome.

(c) 1997 American Health Consultants. All rights reserved.

No Comments